{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:36:11Z","timestamp":1758702971787,"version":"3.40.2"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.jpba.2012.03.001","type":"journal-article","created":{"date-parts":[[2012,3,10]],"date-time":"2012-03-10T18:45:29Z","timestamp":1331405129000},"page":"232-239","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography\u2013tandem mass spectrometry"],"prefix":"10.1016","volume":"66","author":[{"given":"Jinfeng","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caisheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2012.03.001_bib0005","first-page":"372","article-title":"Synthesis and antioxiactivity of squamosamide cycnc analogs","volume":"26","author":"Xie","year":"2004","journal-title":"Acta Acad. Med. Sin."},{"key":"10.1016\/j.jpba.2012.03.001_bib0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuropharm.2006.08.020","article-title":"The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells","volume":"52","author":"Zhang","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpba.2012.03.001_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1385\/MN:31:1-3:295","article-title":"Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism","volume":"31","author":"Feng","year":"2005","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jpba.2012.03.001_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2006.11.015","article-title":"The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells","volume":"561","author":"Zhang","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpba.2012.03.001_bib0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.brainres.2011.01.093","article-title":"FLZ, a novel HSP27 and HSP70 inducer, protects SH-SY5Y cells from apoptosis caused by MPP(+)","volume":"1383","author":"Kong","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.jpba.2012.03.001_bib0030","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.neuroscience.2011.11.036","article-title":"FLZ protects dopaminergic neuron through activating protein kinase B\/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models","volume":"202","author":"Bao","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpba.2012.03.001_bib0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-2094-5-21","article-title":"Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity","volume":"5","author":"Zhang","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.jpba.2012.03.001_bib0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/aps.2010.3","article-title":"The novel squamosamide derivative FLZ enhances BDNF\/TrkB\/CREB signaling and inhibits neuronal apoptosis in APP\/PS1 mice","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jpba.2012.03.001_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/JAD-2009-1133","article-title":"A natural squamosamide derivative FLZ reduces amyloid-beta production by increasing non-amyloidogenic AbetaPP processing","volume":"18","author":"Hou","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jpba.2012.03.001_bib0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1389200043489126","article-title":"Drug transport at the blood\u2013brain barrier and the choroid plexus","volume":"5","author":"Graff","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jpba.2012.03.001_bib0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1537-1891(02)00201-X","article-title":"Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood\u2013brain barrier","volume":"38","author":"Demeule","year":"2002","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.jpba.2012.03.001_bib0060","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.107.019257","article-title":"Quantitative investigation of the role of breast cancer resistance protein (Bcrp\/Abcg2) in limiting brain and testis penetration of xenobiotic compounds","volume":"36","author":"Enokizono","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2012.03.001_bib0065","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1124\/mol.107.034751","article-title":"Effect of breast cancer resistance protein (Bcrp\/Abcg2) on the disposition of phytoestrogens","volume":"72","author":"Enokizono","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jpba.2012.03.001_bib0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3940(02)00423-8","article-title":"P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood\u2013brain barrier: evidence from microdialysis experiments in rats","volume":"327","author":"Potschka","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jpba.2012.03.001_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-glycoprotein, a gatekeeper in the blood\u2013brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.jpba.2012.03.001_bib0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2004.08.001","article-title":"Delivery of therapeutic agents to the central nervous system: the problems and the possibilities","volume":"104","author":"Begley","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2012.03.001_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood\u2013brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.jpba.2012.03.001_bib0090","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/bmc.1004","article-title":"Establishment of a HPLC method for preclinical pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rats","volume":"22","author":"Li","year":"2008","journal-title":"Biomed. Chromatogr."},{"year":"2005","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1016\/j.jpba.2012.03.001_bib0095"},{"key":"10.1016\/j.jpba.2012.03.001_bib0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1476-5381.1986.tb10199.x","article-title":"Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system","volume":"87","author":"Brown","year":"1986","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpba.2012.03.001_bib0105","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.103.053504","article-title":"Evaluation of the blood\u2013brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques","volume":"307","author":"Raje","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2012.03.001_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuro.2011.01.003","article-title":"Alpha-synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of parkinson disease","author":"Covy","year":"2011","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jpba.2012.03.001_bib0115","doi-asserted-by":"crossref","first-page":"e15251","DOI":"10.1371\/journal.pone.0015251","article-title":"The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis","volume":"5","author":"Panneton","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2012.03.001_bib0120","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(24)34974-2","article-title":"Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities","volume":"290","author":"Dantzig","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2012.03.001_bib0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.10792","article-title":"Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979","volume":"103","author":"Shepard","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jpba.2012.03.001_bib0130","first-page":"417","article-title":"Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C","volume":"1","author":"Allen","year":"2002","journal-title":"Mol. Cancer. Ther."},{"key":"10.1016\/j.jpba.2012.03.001_bib0135","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/jpet.109.154781","article-title":"P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib","volume":"330","author":"Chen","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2012.03.001_bib0140","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1158\/1078-0432.CCR-07-1335","article-title":"P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan","volume":"13","author":"de Vries","year":"2007","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708512001240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708512001240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T23:14:30Z","timestamp":1742685270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708512001240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":28,"alternative-id":["S0731708512001240"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2012.03.001","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}